Clinical Trial

A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors

Name: A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors — clinical trial record (NCT07038005)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study includes two cohorts, respectively evaluating safety, tolerability and preliminary efficacy of intravenous and subcutaneous administration of SPGL008.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-06-25.

Status change: Not Yet Recruiting → Recruiting 2026-02-05

Trial Details

NCT Number	NCT07038005
Lead Sponsor	Shenyang Sunshine Pharmaceutical Co., LTD. Collaborators: Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd.
Conditions	Advanced Malignant Tumors
Enrollment	96 participants
Start Date	2025-07-30
Primary Completion	2026-09-22 (estimated)
Study Completion	2027-06-08 (estimated)
Updated on ClinicalTrials.gov	2026-02-09